Abstract
The clinical tolerability profiles of cyclosporine A (CsA) ophthalmic emulsions differ markedly between anionic (Restasis®, 0.05% CsA) and cationic (Ikervis®, 0.1% CsA) formulations, despite delivering the same active compound. Anionic emulsions are more frequently associated with transient blurred vision, whereas cationic emulsions are more frequently associated with instillation-site pain. The mechanistic basis for this divergence has not been clearly defined, and conventional evaluation has relied on animal-based irritation assays or large clinical trials. This Commentary proposes a two-phase physicochemical interpretive framework, aligned with New Approach Methodologies (NAMs) and Integrated Approaches to Testing and Assessment (IATA), in which rotational rheometry is used to characterize early instillation-phase behavior (0–5 min) and gas chromatography–mass spectrometry (GC–MS) is used to characterize sustained post-instillation-phase features (5–30 min). Preliminary observations on Restasis, Ikervis, and a 0.5% carboxymethylcellulose-sodium artificial-tear reference (a nonionic, nonsurfactant, low-nociceptive physicochemical control) are presented as supporting context. Restasis exhibited substantially higher viscosity than Ikervis across all shear rates, whereas Ikervis and the CMC reference showed comparable high-shear viscosity despite markedly different reported tolerability—a viscosity–discomfort dissociation. GC–MS putatively identified a long-chain tertiary amine signal exclusively in Ikervis (retention time ≈13.0 min), which was absent in Restasis and the CMC reference. The proposed framework is hypothesis-generating rather than mechanistically conclusive; it is intended to support future targeted validation studies rather than replace clinical evaluation. GC–MS may serve as a useful complementary fingerprinting tool within NAM/IATA-aligned ophthalmic formulation assessment.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
